INSIGHTS ON DRUG DEVELOPMENT

• Advanced Therapies Going Mainstream: Are We There Yet?

  Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.

• Unlocking The Future: Exploring Cutting-Edge Cell And Gene Therapies

  Explore the transformative potential of cutting-edge cell and gene therapies, focusing on CAR-T cell therapy, CRISPR-Cas9 gene editing, and other advanced approaches.

• Thunderstruck By Antibody-Drug Conjugates

  Antibody-drug conjugates are transforming cancer treatment by targeting tumors directly to reduce side effects. Discover how they affect neighboring cells, which can enhance treatment efficacy and eliminate tumor cell populations.

• Walk-Away Monitoring Of Cytotoxicity, Viability, And Apoptosis

  Real-time cell health monitoring reveals how drug dose and timing impact apoptosis, necrosis, and viability. Explore how automated workflows help pinpoint mechanistic toxicity windows.

• Studying The Spatial Architecture Of Glioblastoma

  3/24/2025

  Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).

• Native SEC-MALS Characterization Using A Chromatography Data System

  5/7/2026

  Native SEC‑MALS offers a calibration‑free way to accurately characterize peptide oligomers, helping scientists distinguish true higher‑order structures while avoiding bias.

• Assessing Production And Stability Of Antibody Drug Conjugate Platforms

  9/24/2025

  ADCs with similar antibody sequences can behave differently due to linker and payload choices. Analytical tools reveal structural and stability differences critical to therapeutic performance.

• A Patented Process For Intermediates Useful For Upadacitinib

  2/18/2026

  Discover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.

• Thermofluor Screening For Injectable Protein Formulations

  9/15/2025

  The results herein highlight thermofluor screening as a versatile and efficient platform for rational formulation of injectable biologics through the acceleration of stable drug product development.